Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Declines By 72.6%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large drop in short interest in May. As of May 29th, there was short interest totaling 30,887 shares, a drop of 72.6% from the May 14th total of 112,539 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 560,221 shares, the days-to-cover ratio is presently 0.1 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC traded down $0.00 during trading hours on Thursday, hitting $0.05. 265,307 shares of the company were exchanged, compared to its average volume of 287,926. The company has a market capitalization of $23.47 million, a PE ratio of 0.09 and a beta of -0.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.11 and a quick ratio of 0.11. The firm has a fifty day simple moving average of $0.04 and a 200-day simple moving average of $0.06. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last released its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 earnings per share for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.